GYNECOLOGIC TUMOR-MARKERS

被引：14

作者：

OLT, GJ ^{[1
]}

BERCHUCK, A ^{[1
]}

BAST, RC ^{[1
]}

机构：

[1] DUKE UNIV,MED CTR,DUKE COMPREHENSIVE CANC CTR,DEPT OBSTET & GYNECOL,BOX 3079,DURHAM,NC 27710

来源：

SEMINARS IN SURGICAL ONCOLOGY | 1990年 / 6卷 / 06期

关键词：

CA; 125; cancer antigen; human chorionic gonadotropin; lipid‐associated sialc acid; ovarian carcinoma‐associated antigen; peptide growth factors; radionuclide imaging; squamous cell; TA‐4;

D O I：

10.1002/ssu.2980060604

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The advent of monoclonal technology has increased the potential utility of antibody‐dependent tumor marker assays in gynecologic oncology. The availability of unlimited quantities of several pure monoclonal antibodies directed against novel epitopes on tumor‐associated antigens has permitted development of highly sensitive assays for serum markers. Traditional assays for human chorionic gonadotropin (hCG), NB/70K and TA‐4 have been improved. CA 125 has provided a useful first‐generation marker for monitoring ovarian cancer and triaging patients with pelvic masses, despite limitations in sensitivity and specificity. In the next decade, the challenge is to identify new markers that will complement CA 125 in monitoring ovarian cancer and facilitate screening for occult early‐stage disease. Strategies involving multiple markers and modalities may be required. Some markers may emerge through a more fundamental knowledge of the biology of gynecologic neoplasms, including the expression of growth factors and their receptors. Finally, the application of monoclonal antibodies to immunohistochemistry and radionuclide imaging also may provide new areas of diagnostic application for monoclonal antibodies in gynecologic oncology. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company

引用

页码：305 / 313

页数：9

共 74 条

[61]

Epenetos AA, Snook D, Hooker G, Et al., Indium‐111 labelled monoclonal antibody to placental alkaline phosphatase in the detection of neoplasms of testis, ovary, and cervix, Lancet, 2, pp. 350-353, (1985)

[62]

Baum RP, Lorenz M, Hottenrott C, Et al., Radioimmunoscintigraphy using monoclonal antibodies to CEA, CA 19‐9 and CA 125, Int J Biol Markers, 3, pp. 177-184, (1988)

[63]

Hunter RE, Doherty P, Griffin TW, Et al., Use of indium‐111‐labeled OC‐125 monoclonal antibody in the detection of ovarian cancer, Gynecol Oncol, 27, pp. 325-339, (1987)

[64]

Pateisky N, Philipp K, Skodler WD, Et al., Radioimmunodetection in patients with suspected ovarian cancer, J Nucl Med, 26, pp. 1369-1376, (1985)

[65]

Jackson PC, Pitcher EM, Davies JO, Et al., Radionuclide imaging of ovarian tumours with a radiolabelled (123I) monoclonal antibody (NDOG2), Eur J Nucl Med, 11, pp. 22-28, (1985)

[66]

Granowska M, Britton KE, Shepherd JH, Et al., A prospective study of 123I‐labelled monoclonal antibody imaging in ovarian cancer, J Clin Oncol, 4, pp. 730-736, (1986)

[67]

Haisma HJ, Moseley KR, Battaile AI, Et al., Biodistribution, pharmacokinetics, and imaging of 131I‐labelled OC 125 in ovarian cancer, Int J Cancer (Supp), 2, pp. 109-113, (1988)

[68]

Symonds EM, Perkins AC, Pimm MV, Et al., Clinical implications for immunoscintigraphy in patients with ovarian malignancy: A preliminary study using monoclonal antibody 79IT/36, Br J Obstet Gynaecol, 92, pp. 270-276, (1985)

[69]

Powell MC, Perkins AC, Pimm MV, Et al., Diagnostic imaging of gynecologic tumors with the monoclonal antibody 79IT/36, Am J Obstet Gynecol, 157, pp. 28-34, (1987)

[70]

Shepherd JH, Granowska M, Britton KE, Et al., Tumour‐associated monoclonal antibodies for the diagnosis and assessment of ovarian cancer, Br J Obstet Gynaecol, 94, pp. 160-167, (1987)

← 1 2 3 4 5 6 7 8 →